A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of...
A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of Propofol, marking the third verdict against Baxter International (BAX -1.2%) and Teva Pharmaceuticals (TEVA +0.7%) over an outbreak in the state tied to use of the drug. An attorney for Teva passes off blame to doctors: "It’s not a vial problem... it’s a practice problem."
From other sites
at Zacks.com (Fri, 1:40PM)
at Zacks.com (Mar 17, 2015)
at Zacks.com (Mar 9, 2015)
at Nasdaq.com (Mar 6, 2015)
at Nasdaq.com (Feb 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs